Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Summary

This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

Timeline

Start

2024-10-15

Primary completion

2026-05-28

Completion

2027-02-04

Outcome

Met primary endpoint

release “The Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 for 60 mg sonelokimab.” moonlaketx.com ↗

Drugs

Indications